Source: Market Exclusive

Zosano Pharma: ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Other Events

On June 13, 2020, Zosano Pharma Corporation (the “Company”) announced that new post-hoc efficacy analyses of QtryptaTM, the Company’s lead investigational product candidate for the acute treatment of migraine, would be presented as a virtual oral presentation on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating


Zosano Pharma is a clinical-stage biopharmaceutical company that researches, develops and commercializes novel therapeutics to treat migraines. Read more